EMA/195549/2014

European Medicines Agency decision

P/0117/2014

of 6 May 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for febuxostat (Adenuric) (EMEA-001417-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0117/2014

of 6 May 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for febuxostat (Adenuric) (EMEA-001417-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Menarini International Operations Luxembourg S.A. on 15 February 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 March 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for febuxostat (Adenuric), film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for febuxostat (Adenuric), film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for febuxostat (Adenuric), film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, L-1611 - Luxembourg, Luxembourg.

Done at London, 6 May 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/18235/2014

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001417-PIP01-12

Scope of the application

Active substance(s):

Febuxostat

Invented name:

Adenuric

Condition(s):

Treatment of hyperuricaemia

Prevention of hyperuricaemia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Menarini International Operations Luxembourg S.A.

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Menarini International Operations Luxembourg S.A. submitted for agreement to the European Medicines Agency on 15 February 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 March 2013.

Supplementary information was provided by the applicant on 20 December 2013. The applicant proposed modifications to the paediatric investigation plan and waiver.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 21 March 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of hyperuricaemia

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- for film-coated tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

1.2. Condition: prevention of hyperuricaemia

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- for film-coated tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition: treatment of hyperuricaemia

2.1.1. Indication(s) targeted by the PIP

Prevention or treatment of hyperuricaemia in children at intermediate or high risk of Tumour Lysis Syndrome (TLS) affected by hematologic malignancies.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	**Study 1:** Development of an age-appropriate oral solid dosage form.
Non-clinical studies	3	**Study 2:** Dose-range finding juvenile toxicity study in rats.

		Study 3: Definitive juvenile toxicity study in rats aged 6 weeks at study start. **Study 4:** Definitive juvenile toxicity study in rats aged 21 days at study start.
Clinical studies	1	**Study 5:** Open-label, randomized, multi-centre, parallel group study to compare the pharmacokinetics (PK), pharmacodynamics (PD) and safety of febuxostat between paediatric patients from 6 to less than 18 years of age and adults.
Extrapolation, modelling and simulation studies	1	**Study 6:** PK/PD modelling and simulation analysis.

2.2. Condition: prevention of hyperuricaemia

2.2.1. Indication(s) targeted by the PIP

Prevention or treatment of hyperuricaemia in children at intermediate or high risk of Tumour Lysis Syndrome (TLS) affected by hematologic malignancies.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Film-coated tablet

2.2.4. Measures

Area	Number of studies	Description
Quality-related studies	1	**Study 1:** Same as for condition: treatment of hyperuricaemia.
Non-clinical studies	3	**Study 2:** Same as for condition: treatment of hyperuricaemia. **Study 3:** Same as for condition: treatment of hyperuricaemia. **Study 4:** Same as for condition: treatment of hyperuricaemia.

Clinical studies	1	**Study 5:** Same as for condition: treatment of hyperuricaemia.
Extrapolation, modelling and simulation studies	1	**Study 6:** Same as for condition: treatment of hyperuricaemia.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2017
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of hyperuricaemia

Authorised indication(s):

- treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). ADENURIC is indicated in adults.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use